spacer
home > epc > autumn 2018 > right first and every time
PUBLICATIONS
European Pharmaceutical Contractor

Right First and Every Time

In recent years, a number of regulatory agencies, scientific bodies, and healthcare organisations have introduced many initiatives to improve the effectiveness and quality of clinical research. However, challenges are still evident when it comes to balancing safety and efficiency in clinical research. Thus, it has been repeatedly stated that better quality management and a different approach is needed urgently. Evolution needs to be driven for safer, more effective clinical research based on principles of minimising harm, removing waste, and managing variation. This requires a more systematic approach.

Good Clinical Practice (GCP) guidelines are simply not enough to ensure safety nowadays. One of the reasons for this is that these are regulations that offer the workflow of documentation and the structure of clinical trials, but the control over how people are implementing them is far too low. To address this challenge, developing standardisation processes of the investigator sites and a database of these accredited sites came into effect in many clinical trials. This standardisation covers all aspects of documentation, patient engagement, and professional qualification of the organisation, where the clinical trials are going to be conducted. Instead of focussing only on the way the site follows ICH GCP regulation, the efficiency profile of the investigator sites will need to be ensured.

Appropriate, proportionate standards that focus on the things that matter are necessary. Beyond any revisions to the existing guidelines or the creation of new sets of guidance, wider cultural change is required to ensure that guidance is implemented appropriately.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Suzanne Pavon is Chief Quality and Compliance Officer, Executive Vice President of Quality Management, Corporate Compliance, and Legal at TFS. Suzanne is an entrepreneurial leader and senior executive with over 20 years’ global experience in the pharmaceutical, biotechnology, and CRO industry. Previous roles include a number of senior leadership positions in quality management, compliance, and clinical operations. She has worked at Novartis, Clinigen, uniQure, Teva, Sanofi, and Genzyme, including five years working at Mayo Clinic, US, and the King Hussain Cancer Center, Jordan. Suzanne is a graduate of Philadelphia University, US, and Harvard School of Public Health, US, and has earned a PhD in oncology, a PharmD, and Certified Professional in Healthcare Quality status.
spacer
Dr Suzanne Pavon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Bottling Line Expansion to Support Customer Needs

Philadelphia, USA – February 5, 2019 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry, is pleased to announce the expansion of its bottling line capacity at its Commercial Packaging site in Rockford, IL. Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as well as in-line serialization and aggregation in support of increased customer demand. The new expansion will grow the robust bottling operation in Rockford by producing an extra 100 million bottles per year.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement